Dr Borrello completed a Fellowship in Medical Oncology at Johns Hopkins to then assume a faculty position there in the Divisions of Immunotherapeutics and Hematologic Malignancies where he ultimately was the Director of the Myeloma Program. He is currently the director of myeloma, BMT and Cell Therapy at Tampa General Hospital. Major contributions have been in translational immunotherapy having developed a bystander GM-CSF vaccine that was licensed and used in AML, myeloma (MM), lung and CML. Most recently, it was shown that this vaccine could significantly improve PFS in MM patients with minimal disease. He has pioneered the establishment of marrow infiltrating lymphocytes (MILs) as a source of T cells for adoptive T cell therapy in MM and solid tumors and demonstrated the enhanced antigen specificity and fitness of BM-derived T cells as compared to PB T cells. This led to the establishment of several adoptive T cell therapies at Johns Hopkins More recent studies have focused on using MILs in solid tumors and as a source of T cells for CAR-T cell therapy